Revision Date: 12.12.16
REV None
- The bioactive response of Cortoss has not been assessed in any clinical investigation and the results from laboratory or animal testing may not be predictive of human clinical experience.
- Bae, H., et al, A Prospective Randomized FDA-IDE Trial Comparing Cortoss to PMMA for Vertebroplasty: A Comparative Effectiveness Research Study with 24-Months Follow-Up. Spine. 2012; 37(7): 544-550
- An Evaluation of the Safety and Efficacy of an Alternative Material to Polymethylmethacrylate Bone Cement for Vertebral Augmentation. Stryker Literature Number 5702-0004, Rev. 00
- Pomrink, et al., Evaluation of the reaction kinetics of Cortoss, a thermoset cortical bone void ller. Biomaterials, 2003, Vol. 24 (6) 1023-1031.
- Cortoss Bone Augmentation Material: Instructions for Use (IFU)
- Palussière, Jean et al. "Clinical Results Of An Open Prospective Study Of A Bis-GMA Composite In Percutaneous Vertebral Augmentation". European Spine Journal 14.10 (2005): 982-991. Web. 18 Aug. 2016.
- Bae, Hyun et al. "Clinical Experience Using Cortoss For Treating Vertebral Compression Fractures With Vertebroplasty And Kyphoplasty". Spine 35.20 (2010): E1030-E1036. Web.
- Independent lab results from Fluid Dynamics Inc. commissioned by Stryker July 2009. Testing conducted at 20-21° C (68-70° F).
- The Worldwide Orthopaedic Market. Prepared by Knowledge Enterprises. October 2005, p. 11
- Orthopaedic Industry Annual Report: 2008-2009. Orthoworld, Inc. 2009, p. 22
- Effect of the Stryker Venom™ Cannula and Venom™ Electrode combination on Lesion Size and Anesthesia Delivery During Radiofrequency Ablation 1000-025-195 Rev None
